Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

Overview of attention for article published in International Journal of Hematology, November 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 37 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 3,379 followers.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. #lymphoma #lymsm https://t.co/pP5Bnu7Fwn

09 Nov 2019

Reply Repost Favourite

New article: Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. https://t.co/PutzzkTxhS #MMSM #MultipleMyeloma #hematology

09 Nov 2019

Reply Repost Favourite